{"id":734082,"date":"2026-06-13T11:38:17","date_gmt":"2026-06-13T11:38:17","guid":{"rendered":"https:\/\/www.newsbeep.com\/ca\/734082\/"},"modified":"2026-06-13T11:38:17","modified_gmt":"2026-06-13T11:38:17","slug":"eyeworld-weekly-june-12-2026","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ca\/734082\/","title":{"rendered":"EyeWorld Weekly, June 12, 2026"},"content":{"rendered":"

Domp\u00e9 announced that it dosed the first patient<\/a> in its Phase 3 clinical trial evaluating cenegermin-bkbj as a treatment for persistent corneal epithelial defect (PCED). According to the company\u2019s press release, the study will enroll 150 adult patients and evaluate cenegermin against placebo with complete epithelial healing being the primary endpoint.<\/p>\n

Back to top<\/a><\/p>\n

Alkeus Pharmaceuticals dosed its first patient in its Phase 3 study<\/a> evaluating oral gildeuretinol (ALK-001) for treatment of Stargardt disease. This randomized, placebo-controlled, double-masked 24-month trial will evaluate safety, efficacy, and pharmacokinetics of gildeuretinol for patients with advanced Stargardt disease and atrophic lesions. The primary endpoint is rate of atrophic lesion growth from 6\u201324 months. A key secondary endpoint is preservation of low luminance visual acuity.<\/p>\n

Back to top<\/a><\/p>\n

Oculis randomized the first patient in its first registrational trial<\/a> evaluating the efficacy and safety of licaminlimab for treatment of dry eye disease, especially for patients with the TNFR1 genotype. The treatment\u2019s effect in the \u201coverall study population\u201d will be evaluated as well. The company described TNFR1 as a \u201ckey receptor mediating TNF\u03b1-driven inflammation and apoptosis,\u201d and noted that licaminlimab \u201chas shown greater clinical response in patients with a specific TNFR1 genotype in Phase 2 trials.\u201d The trial is designed to evaluate the effect of the investigational drug in this specific population with the \u201caim of delivering the first precision medicine treatment in ophthalmology,\u201d according to the company. The trial will enroll about 160 patients, two-thirds of whom will have the TNFR1 genotype. The primary endpoint is change from baseline to Day 29 in the global ocular discomfort severity score in patients with the specified TNFR1 genotype.\u201d The same outcome in the overall study population is a key secondary endpoint.<\/p>\n

Back to top<\/a><\/p>\n

Heidelberg Engineering announced FDA clearance of its SPECTRALIS Software Version<\/a>, which includes a 250 kHz scan speed for OCT angiography with SHIFT Technology, enhanced TruTrack Active Eye Tracking, and a Green Autofluorescence Module. According to the company\u2019s press release, this update is \u201cdesigned to deliver speed, workflow flexibility, and diagnostic depth to multimodal retinal imaging.\u201d<\/p>\n

Back to top<\/a><\/p>\n

Selagine Plasma has received intellectual property rights<\/a> from Selagine Inc. and the University of Chicago, Illinois, to advance toward its goal of developing a pooled plasma platform that would \u201ctransition blood-derived ocular surface therapy from individualized, patient-specific preparation toward a standardized biologic manufacturing model.\u201d<\/p>\n

Back to top<\/a><\/p>\n

ASCRS Live!: This educational dinner series<\/a> is heading to several cities across the U.S. in 2026. Register<\/a> for the next event, June 25 in Chicago, Illinois.
\nASCRS Online Education: The ASCRS CME Education Catalog<\/a> offers a wealth of both CME and non-CME content for ASCRS members. Check out what your colleagues have been watching lately.
\nASCRS Annual Meeting: Hotel rooms are now available for the 2027 ASCRS Annual Meeting. Book your 2027 hotel<\/a> in San Diego early to get your preferred room and location.<\/p>\n

Back to top<\/a><\/p>\n

Robotic cataract surgery has hit some major milestones, and surgeons involved with these projects, as well as those involved with ancillary technologies, discussed them at the 2026 ASCRS Annual Meeting symposium \u201cRobotic Surgery: How Soon and How Good Will It Be?\u201d Read the recap of these discussions in \u201cASCRS symposium covers robotic surgery,\u201d<\/a> an EyeWorld Online Exclusive.<\/p>\n

Back to top<\/a><\/p>\n

The visual and refractive outcomes using the VISUMAX 800 femtosecond laser (Zeiss) to perform KLEx and LASIK performed with the VISUMAX 800 femtosecond laser and the EX500 excimer laser (Alcon) for treatment of myopic astigmatism were compared in a single-center, retrospective, comparative study published in the Journal of Cataract & Refractive Surgery<\/a>. The study included 237 eyes, 133 of which received KLEx and 104 femtosecond-LASIK. The authors found that at 6 months postop, UDVA and CDVA were comparable among the two groups. The KLEx group had a mean spherical equivalent closer to emmetropia compared to the LASIK group (\u22120.04\u00b10.18 D vs. \u22120.10\u00b10.15 D, P=.007), and residual cylinder was lower in the KLEx group. The authors concluded that both procedures performed with the VISUMAX 800 laser provided \u201cexcellent refractive outcomes,\u201d with the KLEx procedures \u201cincorporating an image-guided static cyclotorsion alignment strategy and demonstrating excellent refractive and vector analysis results.\u201d
\nA prospective observational study reviewed reading speed for patients who received binocular PanOptix trifocal IOLs (Alcon) at the time of cataract surgery and those who were age- and education-matched but who didn\u2019t have cataract. The study enrolled 42 patients in the PanOptix group and 42 in the control\/no cataract but presbyopic group. According to the authors, the PanOptix group had \u201csignificantly better binocular reading speed at 3 months postoperatively than the control group (219.81\u00b135.94 vs 174.91\u00b142.21 characters\/min, P< 0.001).\u201d Postop UCVA at all distances and corrected visual acuity at near and intermediate distances were also better in the PanOptix group vs. control. The authors concluded that bilateral PanOptix resulted in \u201csignificantly faster binocular reading speed compared with age-matched presbyopic individuals without near correction.\u201d This study was published in the journal Clinical Ophthalmology<\/a>.<\/p>\n

Back to top<\/a><\/p>\n

Harrow is relaunching VERKAZIA<\/a> (cyclosporine ophthalmic emulsion, 0.1%) for treatment of vernal keratoconjunctivitis.<\/p>\n

Back to top<\/a><\/p>\n

This issue of EyeWorld Weekly was edited by Stacy Jablonski, Liz Hillman, and Ellen Stodola.<\/p>\n

EyeWorld Weekly (ISSN 1089-0319), a digital publication of the American Society of Cataract and Refractive Surgery (ASCRS), is published every Friday, distributed by email, and posted live<\/a> on Friday.<\/p>\n

Medical Editors: Sumit \u201cSam\u201d Garg, MD, Chief Medical Editor, Mitchell Weikert, MD, Cataract Editor, Karolinne Rocha, MD, PhD, Refractive Editor, Julie Schallhorn, MD, Cornea Editor, Manjool Shah, MD, Glaucoma Editor<\/p>\n

For sponsorship opportunities or membership information, contact: ASCRS \u2022 12587 Fair Lakes Circle \u2022 Suite 348 \u2022 Fairfax, VA 22033 \u2022 Phone: 703-591-2220 \u2022 Fax: 703-591-0614 \u2022 Email: ascrs@ascrs.org<\/a><\/p>\n

Mention of products or services in EyeWorld Weekly does not constitute an endorsement by ASCRS.<\/p>\n

Click here<\/a> to view our Legal Notice.<\/p>\n

Copyright 2026, EyeWorld News Service. All rights reserved.<\/p>\n","protected":false},"excerpt":{"rendered":"Domp\u00e9 announced that it dosed the first patient in its Phase 3 clinical trial evaluating cenegermin-bkbj as a…\n","protected":false},"author":2,"featured_media":734083,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[49,48,78958,264003,84,96925,264004,178540],"class_list":["post-734082","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-ca","tag-canada","tag-cornea","tag-dry-eye","tag-health","tag-iol","tag-refractive-surgery","tag-retina"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/734082","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/comments?post=734082"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/734082\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media\/734083"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media?parent=734082"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/categories?post=734082"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/tags?post=734082"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}